Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial).

Trial Profile

Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms SPECIAL
  • Most Recent Events

    • 13 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 26 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Planned end date changed from 1 Feb 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top